Please try another search
Symbol | Exchange | Currency | ||
---|---|---|---|---|
HEM | TSXV | CAD | Delayed | |
HEM | CBOE Canada | CAD | Real-time |
For the three months ended 31 March 2022, Hemostemix Inc revenues was not reported. Net loss increased from C$684K to C$1.6M. Higher net loss reflects Professional fees increase from C$107K to C$961K (expense), Foreign exchange loss (gain) increase from C$17K to C$260K (expense), Stock-based compensation increase of 82% to C$164K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -C$0.01 to -C$0.03.
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -1.33 | -3.67 | -0.92 | -1.4 |
Net Income | -1.64 | -3.22 | -1.04 | -1.34 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 1.35 | 0.56 | 2.39 | 2.91 |
Total Liabilities | 6.86 | 5.85 | 4.62 | 4.56 |
Total Equity | -5.51 | -5.28 | -2.23 | -1.65 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -0.41 | -3.48 | -1.53 | -0.69 |
Cash From Investing Activities | 0.17 | |||
Cash From Financing Activities | 1.16 | 3.27 | 1.8 | 1.12 |
Net Change in Cash | 0.75 | -0.04 | 0.27 | 0.43 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review